Gene therapy trial aims to turn Patients' own cells against rare, aggressive cancers
NCT ID NCT07055477
Summary
This early-stage trial is testing the safety of a new gene therapy for adults with certain T-cell lymphomas that have returned or not responded to prior treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to target a protein (CCR4) found on their cancer cells, and then infuse them back. The main goal is to see if this approach is safe and to find the right dose, with participants being followed for up to 15 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.